Search results for "Drug Reimbursement Evaluation Committee"

South Korea’s First Homegrown CAR-T, Rimqarto, Moves Closer to Coverage with 67% Complete Response Rate

South Korea’s First Homegrown CAR-T, Rimqarto, Moves Closer to Coverage with 67% Complete Response Rate

Curocell announced on Sept. 4 that its chimeric antigen receptor T-cell (CAR-T) therapy Rimqarto (generic name: anbalcabtagene autoleucel) was deemed...
550 Days in Limbo: Groups Demand 100-Day Fast-Track Insurance Coverage for Breakthrough PAH Drug Winrevair

550 Days in Limbo: Groups Demand 100-Day Fast-Track Insurance Coverage for Breakthrough PAH Drug Winrevair

With national health insurance coverage for the new pulmonary arterial hypertension treatment Winrevair (active ingredient: sotatercept) remaining in...
Will Curocell’s First CAR-T Blood Cancer Drug Secure Approval Next Month?

Will Curocell’s First CAR-T Blood Cancer Drug Secure Approval Next Month?

A final decision on the approval of RIMQARTO (anbalcabtagene autoleucel), a chimeric antigen receptor T-cell (CAR-T)...